Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16285864 | 1.00 | KDM4E (0.38) | KDM4EALDH1A1DRD2DRD3LMNA | |
| SCHEMBL21754625 | 1.00 | KDM4E (0.38) | KDM4EALDH1A1DRD2DRD3LMNA | |
| SCHEMBL25093174 | 0.98 | KDM4E (0.37) | KDM4EALDH1A1DRD2DRD3LMNA | |
| SCHEMBL10017901 | 0.93 | KDM4E (0.39) | KDM4EALDH1A1DRD2DRD3LMNA | |
| SCHEMBL863457 | 0.93 | KDM4E (0.39) | KDM4EALDH1A1DRD2DRD3LMNA | |
| SCHEMBL12717539 | 0.93 | KDM4E (0.39) | KDM4EALDH1A1DRD2DRD3LMNA | |
| SCHEMBL738020 | 0.83 | — | — | |
| SCHEMBL463379 | 0.83 | — | — | |
| SCHEMBL738505 | 0.83 | — | — | |
| SCHEMBL14818612 | 0.83 | KDM4E (0.33) | KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230348658-A1 | COPOLYMERS AND TERPOLYMERS OF POST MODIFIED POLYACRYLATES AS EFFICIENT GAS HYDRATE INHIBITORS | SAUDI ARABIAN OIL COMPANY (SA) | 2023-11-02 | — | — | US | disclosed |
| US-20230348658-A1 | COPOLYMERS AND TERPOLYMERS OF POST MODIFIED POLYACRYLATES AS EFFICIENT GAS HYDRATE INHIBITORS | SAUDI ARABIAN OIL COMPANY (SA) | 2023-11-02 | — | — | US | disclosed |
| US-20230112485-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| US-20210355124-A1 | Cyclic compounds as receptor modulating therapeutics and methods and uses thereof | BIONOMICS LIMITED (AU) | 2021-11-18 | — | — | US | disclosed |
| US-10392349-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190119281-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | LOXO ONCOLOGY INC (US) | 2019-04-25 | — | — | US | disclosed |
| WO-2019018186-A1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2019-01-24 | — | — | WO | disclosed |
| US-20190016682-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2019-01-17 | — | — | US | disclosed |
| US-20120142687-A1 | INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | KUGIMIYA AKIRA (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | THE UNIVERSITY OF EDINBURGH (GB) | 2012-04-19 | — | — | US | disclosed |
| US-8153793-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20110015178-A1 | Amido-Thiophene Compounds and Their Use | THE UNIVERSITY OF EDINBURGH (GB) | 2011-01-20 | — | — | US | disclosed |
| US-7871999-B2 | Substituted thiazoles and their use for producing drugs | GRUENENTHAL GMBH (DE) | 2011-01-18 | — | — | US | disclosed |
| US-7842692-B2 | Azaindole derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2010-11-30 | — | — | US | disclosed |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | THE UNIVERSITY OF EDINBURGH | 2010-10-21 | — | — | US | disclosed |
| US-20090197881-A1 | Azaindole Derivative Having PGD2 Receptor Antagonistic Activity | SHIONOGI & CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090176756-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUNENTHAL GMBH (DE) | 2009-07-09 | — | — | US | disclosed |
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119281-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LCK | KDM4E 856/4885ALDH1A1 3044/4885DRD2 4480/4885 |
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | HSD11B1, HSD11B2, HSD3B1 | KDM4E 3805/4885ALDH1A1 361/4885DRD2 3249/4885 |
| US-20190016682-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | KDM4E 2501/4885ALDH1A1 2038/4885DRD2 4187/4885 |
| US-20230112485-A1 | THERAPEUTIC COMPOUNDS | BRDT, BRPF3, SNRPE | KDM4E 3145/4885ALDH1A1 4242/4885DRD2 4721/4885 |
| US-10392349-B2 | Azepane derivatives and methods of treating hepatitis B infections | HAVCR2, HDGF, AZI2 | KDM4E 2501/4885ALDH1A1 2038/4885DRD2 4187/4885 |
| US-20110015178-A1 | Amido-Thiophene Compounds and Their Use | HSD11B1, HSD11B2, HSD17B1 | KDM4E 2053/4885ALDH1A1 328/4885DRD2 2914/4885 |
| US-20210355124-A1 | Cyclic compounds as receptor modulating therapeutics and methods and uses thereof | CHRNA7, CHRNA1, CHRNA5 | KDM4E 3556/4885ALDH1A1 832/4885DRD2 751/4885 |
| US-20090197881-A1 | Azaindole Derivative Having PGD2 Receptor Antagonistic Activity | PTGDR, HRH2, PTGDR2 | KDM4E 1732/4885ALDH1A1 1908/4885DRD2 22/4885 |
| US-20090176756-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | TPMT, SLC5A2, DPP4 | KDM4E 3583/4885ALDH1A1 844/4885DRD2 2020/4885 |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | HSD11B1, HSD11B2, HSD17B1 | KDM4E 2261/4885ALDH1A1 285/4885DRD2 2818/4885 |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | KDM4E 4616/4885ALDH1A1 3733/4885DRD2 4639/4885 |
| US-20120142687-A1 | INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, CYSLTR1, CYSLTR2 | KDM4E 2154/4885ALDH1A1 2398/4885DRD2 26/4885 |
| US-11912723-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | KDM4E 4616/4885ALDH1A1 3733/4885DRD2 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.